Heart Disease Clinical Trials in Philadelphia

Showing 521-540 of 543 trials

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

NCT00159627

The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are refractory to high dose diuretic therapy.

Heart Failure, Congestive

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)52 participantsStarted Aug 2004

Stanford, California, United States • Washington D.C., District of Columbia, United States • Sarasota, Florida, United States +7 more locations

TERMINATEDPhase 4< 1 mile

Lansoprazole Preventing Gastroduodenal Stress Ulcerations

NCT00220909

The primary objective of this study is to determine whether lansoprazole, administered intravenously, can protect patients undergoing cardiac surgery from the development of and/or progression of previously undetected acid/peptic disorders (erosive esophagitis, gastric ulcer, duodenal ulcer, diffuse gastritis, duodenitis) as measured by the Lanza score and LA classification for esophageal injury. The secondary objectives of this study are: 1. To determine if intravenous lansoprazole protects against the development of clinically important gastrointestinal bleeding in this population (overt bleeding or requiring blood transfusion). 2. To determine if intravenous lansoprazole maintains the intragastric pH above that for placebo throughout the study period.

Patients Undergoing Elective Coronary Artery Bypass Graft

Temple University40 participantsStarted Sep 2005

Philadelphia, Pennsylvania, United States

COMPLETEDNA< 1 mile

Lipid Lowering in Patients With Statin Intolerance

NCT00405769

This study will attempt to further validate a clinical treatment plan to lower LDL values using non-prescription supplements combined with a lifestyle change and education program which could represent an alternative approach to improve compliance in group of people who are unable to take traditional medication to lower cholesterol.

HyperlipidemiaCoronary Artery Disease

Chestnut Hill Health System64 participantsStarted Jan 2007

Philadelphia, Pennsylvania, United States

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

Lansoprazole Preventing Gastroduodenal Stress Ulcerations

Lipid Lowering in Patients With Statin Intolerance

Heart Disease Trials in Other Cities

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure

Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.

Predictor of Advanced Subclinical Atherosclerosis

Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures

InSync Implantable Cardioverter Defibrillator Registry: Cardiac Resynchronization Therapy

ARISE - Aggressive Reduction of Inflammation Stops Events

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease

Long-Term Follow-up Study of Patients Who Received PB127 Ultrasound Imaging Agent

Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007

Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function

Biomarkers in Acute Heart Failure

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease

Other Conditions in Philadelphia